pp-239 Solution for infusion
Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Comments
Indication: Advanced Solid Tumors (5T4-expressing) / Clinical stage: Phase 1b/2a (Phase 2 component active) (5-STAR 1-01 trial) / Modality: Biologic - antibody-drug conjugate (ADC) with tubulysin payload / Mechanism & Target: 5T4-directed tubulysin ADC / Route & form: IV / Differentiation: next-generation ADC platform; broad solid tumor applicability
Manufacturer #39442
| Clinical-stage biotechnology company developing next-generation antibody-drug conjugates for oncology. Advances proprietary linker-payload platform targeting solid tumors with differentiated therapeutic profiles. Pipeline programs supported by a major global strategic partnership. |
None